Ritonavir (CAS 155213-67-5)/Antiviral

Ritonavir (CAS 155213-67-5) is a high-purity pharmaceutical API classified as a potent CYP3A4 inhibitor, featuring a peptidomimetic molecular structure originally developed as a protease inhibitor for HIV. Its primary clinical role is as a pharmacokinetic booster: it selectively inhibits cytochrome P450 3A4 (CYP3A4) enzyme activity, reducing hepatic metabolism of co-administered antivirals to enhance their bioavailability, prolong half-life, and maintain therapeutic concentrations. Unlike standalone antivirals, it acts synergistically to amplify efficacy while minimizing dosage requirements of partner drugs.

It caters to the core needs of antiviral drug manufacturers, infectious disease therapy developers, and pharmaceutical formulators. Widely used in combination therapies for HIV/AIDS and as a key booster in COVID-19 treatments (e.g., with nirmatrelvir), it aligns with demand for reliable drug-drug interaction modifiers. Produced under strict GMP standards, each batch undergoes rigorous purity and enzyme inhibition potency testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing antiviral therapy optimization, this Ritonavir API serves as a critical raw material for advancing boosted antiviral formulations.